Artiva Biotherapeutics, INC S-1 registration statements

Artiva Biotherapeutics files a registration statement to increase the aggregate number of shares offered by 6,003,000 following its initial public offering.

Artiva Biotherapeutics is seeking to raise $116.8 million through an initial public offering to advance its NK cell-based therapies for autoimmune diseases and cancers.

Artiva Biotherapeutics, a clinical-stage biotechnology company, has filed an S-1 registration statement for an initial public offering to fund the development of its natural killer (NK) cell-based therapies for autoimmune diseases and cancers.